Table 4.
Completion rate and the duration of the administration period in which S-1 should be administered at the prescribed dose without suspension or discontinuation during first treatment course (28 days)
| Group | Colon cancer | Gastric cancer | Total | |||
|---|---|---|---|---|---|---|
| Control | C/T | Control | C/T | Control | C/T | |
| Completion rate of first course of treatment (cases) | 10/24 | 20/22 | 1/7 | 4/9 | 11/31 | 24/32 |
| Percent (%) | 41.7 | 90.9** | 14.3 | 44.4 | 35.5 | 75.0** |
| Duration (days) | 21.0 ± 7.4 | 26.8 ± 3.8** | 16.3 ± 8.0 | 21.1 ± 6.8 | 20.0 ± 7.7 | 24.8 ± 5.8** |
Duration was expressed as mean ± SD and compared using the t test
C/T cystine and theanine
** p < 0.01 vs. control